Are New Alzheimer’s Drugs All They Promise To Be?

Researchers question the impact of amyloid immunotherapy on Alzheimer’s, highlighting the small benefits versus significant risks and costs.

Despite regulatory approval by the FDA, other bodies like the EMA express reservations, reflecting broader concerns about these treatments’ real-world efficacy.

Alzheimer’s Immunotherapy Challenges
Cambridge researchers have cast doubt on whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the impact of Alzheimer’s disease.

Writing in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the team from Cambridge Public Health argues that substantial challenges including the risk-benefit ratio, limited eligibility, and high cost of the roll-out will limit any benefits of these treatments.